JAZZ PHARMACEUTICALS PLC (JAZZ)       154.32  +1.32 (+0.86%)

154.32  +1.32 (+0.86%)

IE00B4Q5ZN47 - Common Stock

JAZZ PHARMACEUTICALS PLC154.32

NASDAQ:JAZZ (11/28/2022, 12:36:07 PM)+1.32 (+0.86%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) N/A N/A
Ins Owners 2.92% Inst Owners 91.2%
Market Cap 9.72B Shares 62.97M
PE 8.86 Fwd PE 8.38
Dividend Yield N/A Analysts 82.5
IPO 01-18 2012-01-18

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JAZZ Daily chart

Company Profile

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 3,200 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).

Company Info

JAZZ PHARMACEUTICALS PLC

Fifth Fl, Waterloo Exchange, Waterloo Road

DUBLIN DUBLIN D04

P: 35316347800.0

CEO: Bruce C. Cozadd

Employees: 3200

Website: https://www.jazzpharma.com/

JAZZ News

News Image6 hours ago - Jazz Pharmaceuticals plcJazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,...

News Image8 hours ago - The Motley FoolWant to Double Your Money? Buying These Stocks Could be a Genius Move

These stocks are undervalued considering their long-term growth potential.

News Image4 days ago - The Motley FoolPrediction: This Growth Stock Could Double in 2023

The next year should be a busy one for this drugmaker.

News Image5 days ago - MarketBeatThree CBD Stocks to Dominate a Budding Industry

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

News Image7 days ago - Market News VideoFirst Week of January 2023 Options Trading For Jazz PharmaceuticalsNews Image8 days ago - The Motley FoolGot $500? 3 Growth Stocks to Buy That Could Double Your Money

Innovative products and services could keep these companies growing.

JAZZ Twits

Here you can normally see the latest stock twits on JAZZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example